Drug Trial Radar · NCT06730061
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Actual
Start
Jan 16, 2025
Primary completion
Dec 17, 2026
Study completion Apr 8, 2032
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease. PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. In this study all participants will receive a daily dose of elafibranor (the study intervention). The main aim of this study is to determine if elafibranor reduces alkaline phosphatase (ALP) and total bilirubin levels. High ALP and bilirubin levels in the blood can indicate liver disease. There will be 4 periods in this study: A screening period (up to 10 weeks) to assess whether the participant can take part. A treatment period (52 weeks) where all eligible participants will receive elafibranor. A variable treatment extension period (2-5 years) from End Of Treatment (EOT) period up to the commercial availability of elafibranor in Japan. A follow-up period (4 weeks) where participants' health will be monitored. Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a non-invasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to approximately 6 years
Conditions
- Primary Biliary Cholangitis
Interventions
ElafibranorDrug
Tablet of 80 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULNTime frame: At Week 52
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Nippon Medical School - Chiba Hokusoh Hospital
Chiba, Japan
Fukushima Medical University Hospital
Fukushima, Japan
Chugoku Rosai Hospital
Hiroshima, Japan
Teine Keijinkai Hospital
Hokkaido, Japan
Kagawa University Hospital
Kagawa, Japan
Kagoshima University Hospital
Kagoshima, Japan
Shinshu University Hospital
Nagano, Japan
National Hospital Organization Nagasaki Medical Center
Nagasaki, Japan
Nara Medical University Hospital
Nara, Japan
Nagaoka Red Cross Hospital
Niigata, Japan
Niigata University Medical & Dental Hospital
Niigata, Japan
National Hospital Organization Osaka National Hospital
Osaka, Japan
Hamamatsu University Hospital
Shizuoka, Japan
Juntendo University Hospital
Tokyo, Japan
Teikyo University Hospital
Tokyo, Japan
Tokyo Metropolitan Komagome Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.